Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI

Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature

“…This study did not assess MACE or other clinical outcomes but did show that this DAPT regimen produced more potent inhibition than TAPT in a high-risk STEMI population with no difference in the incidence of bleeding [61].…”

“…On that note, two recent, small, single-center, prospective, randomized trials compared TAPT to a new regimen of DAPT consisting of aspirin and prasugrel in Korean patients with ST-segment elevation MI (STEMI) undergoing primary PCI [61,62]. The first study by Yang et al [61] included 40 patients with a mean age of 59.5 ± 12.5 years, 80 % men, and 30 % with diabetes.…”

“…The first study by Yang et al [61] included 40 patients with a mean age of 59.5 ± 12.5 years, 80 % men, and 30 % with diabetes. Patients received loading doses of aspirin 300 mg and prasugrel 60 mg immediately after randomization to the DAPT group.…”

“…More patients (total of six) in the DAPT group experienced puncture site hematoma compared to TAPT (20 vs. 10 %; p = 0.66). Of those six patients with puncture site hematomas, four in the DAPT and one in the TAPT had PRU \100 and two in each group received primary PCI via the femoral artery [61].…”

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome in the real world: Data from the Berlin AFibACS Registry

“…The WOEST Study [16], which included AFib patients treated with a stent, and a Danish data [17] analysis with AFibACS patients showed that bleeding risk and mortality were higher in patients treated with triple therapy than those treated with anticoagulation medication and clopidogrel alone (double therapy), with no difference in stent thrombosis and thromboembolic risk. Also, a small study by Yang et al [18] showed that a dual therapy with aspirin and prasugrel was more potent than a triple therapy with aspirin, clopidogrel and cilostazol.…”